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Background: In Greece, several new childhood vaccines were introduced recently but were reimbursed gradually
and at different time points. The aim of this study was to assess immunization coverage and identify factors
influencing complete and age-appropriate vaccination among children attending public nurseries in the municipal
district of Athens.
Methods: A cross-sectional study, using stratified sampling was performed. Immunization history was obtained
from vaccination booklets. Demographic and socioeconomic data were obtained from school registries and
telephone interviews. Vaccination rates were estimated by sample weighted proportions while associations
between complete and age-appropriate immunization and potential determinants by logistic regression analysis.
Results: A total of 731 children (mean age: 46, median: 48, range: 10–65 months) were included. Overall
immunization coverage with traditional vaccines (DTP, polio, Hib, HBV, 1st dose MMR) was satisfactory, exceeding
90%, but the administration of booster doses was delayed (range: 33.7- 97.4%, at 60 months of age). Complete
vaccination rates were lower for new vaccines (Men C, PCV7, varicella, hepatitis A), ranging between 61-92%. In
addition, a significant delay in timely administration of Men C, PCV7, as well as HBV was noted (22.9%, 16.0% and
27.7% at 12 months of age, respectively). Child’s age was strongly associated with incomplete vaccination with all
vaccines (p< 0.001), while as immigrant status was a predictor of incomplete (p=0.034) and delayed vaccination
(p<0.001) with traditional vaccines. Increasing household size and higher maternal education were negatively
associated with the receipt of all and newly licensed vaccines, respectively (p=0.035).
Conclusions: Our findings highlight the need to monitor uptake of new vaccines and improve age- appropriate
administration of booster doses as well as early vaccination against hepatitis B. Immigrant status, increased
household size and high maternal education may warrant targeted intervention.
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Immunization is one of the most effective public health
tools, leading to reduced infant and childhood morbidity
and mortality, caused by vaccine preventable diseases
worldwide [1-4]. However, outbreaks of vaccine preventable
diseases continue to occur in developed countries, and this
may be attributed to unimmunized or under-immunized
subpopulations despite high overall vaccination coverage
[5-9]. Several underlying factors for suboptimal vaccine
uptake have been described, but are complex and present
diversities among different countries, and population
groups [10-16]. It is, therefore, essential to monitor vac-
cination coverage regularly and identify reasons that
contribute to delay or non- vaccination at local levels,
in order to develop appropriate strategies to address
the needs of susceptible populations.
In Greece, vaccines included in the National Immunization
Programme (NIP) are universally recommended and are
provided free of charge to all resident children, including
immigrants. Children can be vaccinated in the private
sector or primary health centers and health insurance
clinics, the latter two at no additional cost. Vaccinations
are recorded in health booklets, but there is no routine
nationwide monitoring and no official vaccine reminder
system.
As in most developed countries, the Hellenic immu-
nization schedule has become more complex in the last
decade, with the introduction of new vaccines and
recommendation of more doses of existing vaccines.
It is noteworthy that reimbursement of new vaccines
has occurred recently, mostly in a gradual and non-
simultaneous process. Therefore, compliance with newly
recommended vaccines and associated factors has not
been well documented.
Several local and one nationwide study assessing
vaccination coverage with old vaccines (DTP/DTaP,
OPV/IPV, MMR, Hib and hepatitis B) in pre- school
and first grade grammar school children have been
published in our country but have not addressed factors
influencing under immunization [17-20]. According to a
national survey performed in 2006 among 6- year olds,
various socioeconomic factors, rather than parental
attitudes and beliefs towards vaccines, were identified
as predictors for incomplete and delayed immunizations
[21]. Since then, new multivalent vaccines, as well as conju-
gated meningococcal C (Men C), 7-valent pneumococcal
(PCV7), varicella (Var) and hepatitis A vaccines (HAV),
licensed between 1999 and 2004, were gradually
incorporated in the Hellenic NIP. Men C and PCV7
were partially reimbursed in 2005, Var in 2006, and
all others, including HAV, were fully compensated in
2008. Moreover, a significant increase in the immi-
grant population, including children, originating from
countries with limited vaccine resources, has occurredduring the last years [22,23]. At present, data concerning
immunization uptake of newer vaccines and related
determinants remain insufficient.
The aim of this study was to assess immunization
coverage and identify factors affecting complete and
age-appropriate vaccination among a large population
of children attending public nurseries in the munici-
pal district of Athens, after the introduction of a full
reimbursement policy of new vaccines.
Methods
A cross-sectional study was undertaken using stratified
sample design in all public nurseries of the Municipality
of Athens, Greece during the school year 2010–2011.
The above area consists of 98 nursery schools with a
total of 5,401 registered pupils of middle and low income
families and is further divided into seven subregions.
Nurseries were equally stratified into all seven municipal
subregions. These were further subdivided by the child’s
gender into boys and girls in order to better reflect the
children’s gender distribution by region. On the day of
population recording, a total of 4,165 pupils were present,
but only 3,399 were considered for further evaluation,
those whose parents had presented a health booklet.
The minimum required sample size was estimated,
using Snedecor & Cochran’s formula for random
sampling from finite populations [24]. Final sample
consisted of 731 children (368 boys and 363 girls)
with 90% power and +/− 10% estimate of true
proportion.
Children were randomly sampled from each stratum,
as opposed to the entire 3,399 children, in order to extract
the number of subjects estimated by sample stratification,
followed by personal telephone interviews from children’s
guardians. In the case of incorrect phone number or
non-reply, following a total of five repeated attempts,
simple random sampling was repeated, in order to
complete the originally calculated number of 731 individ-
uals. The sampling stopped once the minimum sample size
was achieved.
All school teachers invited to participate, were
informed through interactive sessions organized by
the investigators at the beginning of the school year.
Following an explanatory letter, all parents/guardians of
children of the selected schools were asked to take
part in the study by presenting their child’s vaccin-
ation booklet and by answering to a subsequent telephone
interview.
Data collection
A structured questionnaire completed by the investiga-
tors was used. Basic demographic data were collected
from school registries on the day of school visit. De-
tailed vaccination history and use of combination
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Parental/guardian attitudes towards immunization and
additional information were gathered on a second occasion
by telephone interview.Definitions of vaccination status
Children were considered completely and timely im-
munized according to the 2006 NIP guidelines (see
Additional file 1: Table S1). Definitions of complete
and age- appropriate immunization are presented in
Table 1. We decided to use the 2006 NIP as reference
because the majority of the pupils belonged to this age
group. Assessment of immunization coverage against
hepatitis A was performed separately, since this vaccine
was introduced and fully reimbursed in 2008, for all
infants older than 12 months.Ethical considerations
The study protocol was approved by the ethics committee
of the University of Athens, Faculty of Nursing andTable 1 Definitions of complete and age- appropriate vaccina
Vaccine Complete vaccination
DTP/DTaP
3 doses by the age of 12 months, or
4 doses by the age of 24 months, or
5 doses by the age of 60 months
OPV/IPV
2 or 3 doses by the age of 12 months plus 1 dose ≥ 12 mo
3 doses by the age of 24 months or
4 or 5 doses by the age of 60 months
Hib
2 or 3 doses by the age of 12 months plus
1 dose between ≥ 12 – 23 months, or
2 doses between 12 – 24 months, or
1 dose at the age of ≥ 24 months.
MMR
1 dose between ≥ 12 < 48 months, or
2 doses between ≥ 48 – 60 months
HBV ≥ 3 doses
Men C
2 doses < 12 months, or
1 dose ≥ 12 months
PCV7
3 doses by the age of 12 months, plus
1 dose ≥ 12 – 23 months, or
2 doses from the age of 7 – 12 months, plus
1 dose ≥ 12 – 23 months, or
2 doses between 12 – 23 months, or
1 dose ≥ 24 months
Var
1 dose between ≥ 12 < 48 months, or
2 doses between ≥ 48 – 60 months
HAV ≥ 2 doses at ≥ 12 months
DTP/DTaP: diphtheria, tetanus, pertussis/ acellular pertussis vaccine; OPV/IPV: live at
mumps, rubella vaccine; Hib: haemophilus influenzae type b vaccine; Men C: conjug
vaccine; Var: varicella vaccine; HAV: hepatitis A vaccine.the review board of the Municipal Nursery of Athens.
Informed consent was implied when parents provided
their child’s health booklet and participated in the
telephone interview that followed.Statistical analysis
In order to examine associations between complete and
age-appropriate vaccination with potential determinants
we, initially, applied simple cross-tabulations and the
X2-test. Weighted proportions were used to account for
the sampling design.
Consequently, we applied multiple logistic regres-
sion models [25] including the child’s actual age at
interview (in years, continuously), father’s nationality
(Greek versus other), mother’s education (high school
or less versus college/university), number of children
in the family (categorically as: 1, 2, 3 or more), use of
multivalent vaccines (3- or 4-valent versus 5- or 6-valent).
Additional variables included the impact of vaccine cost
and the insurance coverage on the decision for vaccinationtion
Age appropriate vaccination at the age of
12 months 24 months 60 months
3 doses 4 doses 5 doses
nths, or
3 doses 3 or 4 doses 4 or 5 doses
2 or 3 doses ≥ 3 doses ≥ 3 doses
- ≥ 1 dose 2 doses
3 doses 3 doses 3 doses
2 or 3 doses ≥ 3 doses ≥ 3 doses
3 doses 4 doses 4 doses
- ≥ 1 dose 2 doses
- 2 doses 2 doses
tenuated/inactivated polio vaccine; HBV: hepatitis B vaccine; MMR: measles,
ated meningococcal C vaccine; PCV7: conjugated pneumococcal 7-valent






≤ 24 27 (3.7)
25 − 48 363 (50.3)













High school or less 433 (59)
College/University 297 (41.1)
IKA: Social Security Institute; * One mother deceased.
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(private pediatrician versus public health clinic/ insurance
doctor) and finally the social security [Social Security
Institute (IKA) versus other]. The choice of the variables
entered in the models was based on the results from an
initial exploratory analysis, possible confounding effects
and likelihood ratio backward selection. Special attention
was paid in order not to include confounders that were
highly correlated (as indicated from the univariate analysis
through either X2 test or the Spearman correlation
coefficient). Possible determinants of interest, such as
the impact of vaccines’ cost on the decision for vaccination,
were entered in the models irrespectively of statistical cri-
teria. For comparability reasons, in the interpretation of the
associations we applied the same model when considering
complete or age- appropriate vaccination. When analyzing
vaccination status for the three newer vaccines, the
influence of vaccine’s cost was not considered as a
possible determinant since there was no variability as
parents of all age appropriate vaccinated children
responded that it did not affect their decision. Statistical
analysis was performed by SPSS for Windows, version 16.0
(SPSS, Chicago, IL, USA).
Results
From October 2010 through November 2011, information
concerning vaccination history was obtained from a total
of 3,399 health booklets available on the day of school
visit (participation rate 81.6%). The final stratified sample
consisted of 731 children, and the response rate was 85%.
The mean age of the individuals on the day of sampling
was 46 months (median, 48 months; range: 10–65 months).
Table 2 illustrates selected demographic characteristics
of the study population. Of the 731 pupils, 504 (68.9%)
were of Greek nationality, 126 (17.2%) were Albanian,
and the remaining 101 (13.8%) originated from other
foreign countries. The majority of children (61%) were
insured with Social Security Institute (IKA). Interestingly,
a relatively high proportion of mothers (41%) were college
or university graduates.
Table 3 shows parental attitudes towards vaccines.
Nearly two thirds of the parents decided to vaccinate
their child in order to offer protection or to prevent disease.
Most parents (66.6%) decided to vaccinate their children at
insurance or public health clinics. Although most guardians
denied that vaccine cost could be a drawback (91.7%),
a high proportion (66.4%) admitted that insurance
reimbursement would have a positive impact on their
decision to vaccinate their child.
Immunization coverage
Observed sample sizes and weighted proportions for both
complete and age- appropriate immunization coverage are
presented in Table 4. Complete immunization rates fordiphtheria, tetanus, pertussis, poliomyelitis, Hib and
hepatitis B were satisfactory overall, exceeding 94%.
However, complete overall coverage for MMR was
lower, reaching 63.7%. Likewise, age- appropriate
immunization rates for the aforementioned vaccines
were satisfactory at the age of 12 months, except for
hepatitis B, but gradually decreased thereafter. Thus,
hepatitis B vaccine uptake did not exceed 27.7% at 12
months but increased with age reaching 86.1% at 24
and 97.4% at 60 months of age.
Among children eligible for varicella vaccination, 435
[61.1%; 95% confidence interval (CI): 57.5%- 64.7%] were
completely immunized, whereas 671 (91.9%; 95% CI:
89.9%- 93.9%) were fully immunized with Men C, 537
(73.1%; 95% CI: 69.9%-76.3%) with PCV7 and 450
(62%; 95% CI: 60.7%- 67.7%) with HAV. In contrast,
age- appropriate immunization with the above vaccines
was significantly lower, ranging between 4 and 71%, the
lowest rates being observed among those vaccines that
were gradually reimbursed (Men C and PCV7) when com-
pared to the ones that were compensated simultaneously
to their implementation (Var, HAV).
Finally, a total of 414 (56.9%) children (95% CI: 53.3%-
60.5%) were fully immunized with all five traditional
vaccines (DTP/DTaP, polio/IPV, Hib, HBV and MMR),
Table 3 Parental attitudes towards vaccines
N (%)
Reasons for vaccinating
Protection, immunity, good health 354 (47.9)
Prevention of infections 162 (22.6)
Pediatrician’s advice 103 (14.4)
It is compulsory 112 (15.1)
Would vaccine cost influence your decision to vaccinate your child?
Yes 75 (10.3)
Probably yes 21 (2.9)
Maybe 118 (15.9)
Probably not 56 (7.7)
No 461 (63.3)
Does insurance reimbursement influence your decision?
Yes 487 (66.4)
No 244 (33.6)
Where do you vaccinate you child?
Private pediatrician* 239 (33.4)
Insurance doctor or clinic† 485 (65.7)
Public health clinic† 7 (0.9)
* Doctor’s fee only, †No additional costs.
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completely immunized with all three recently introduced
vaccines (PCV7, Men C, Var).
Multiple logistic regression analysis
Table 5 presents multiple logistic regression- derived
odds ratios (ORs) and corresponding 95% CIs for the
association between sample characteristics and complete
and age- appropriate immunization for all five traditional
vaccines (DTP/DTaP, IPV/OPV, Hib, MMR and HBV).
Factors negatively associated with complete immunization
coverage with all of the above vaccines, were the child’s
increasing age (p< 0.001) and foreign ethnicity (p= 0.034).
In addition, ethnicity seemed to play a significant role on
age- appropriate vaccination since Greek children had
higher odds to be vaccinated at the age of 24 months
than immigrant children (OR: 2.57; 95% CI: 1.71-3.87,
p< 0.001). Moreover, age- appropriate vaccination rates
increased significantly with the use of multivalent vaccines
both at the ages of 12 (p<0.001) and 24 months (p<0.001).
Finally, children whose parents expressed negative
attitudes concerning vaccine cost, presented lower rates of
timely immunization (statistically significant at the age of
24 months, OR: 0.51, 95% CI: 0.28-0.92, p=0.025).
Multiple logistic regression results assessing complete
and age-appropriate immunization with all three newly
introduced vaccines (Men C, PCV7, Var) are presented
in Table 6. As shown, increasing age remained a negativepredictor for complete (OR: 0.77; 95% CI: 0.65-0.91,
p=0.002) and timely immunization at 12 (OR: 0.47; 95%
CI: 0.35-0.64, p<0.001) and 24 (OR: 0.45; 95% CI: 0.29-0.71,
p<0.001) months of age. Use of multivalent vaccines had
a positive impact on age-appropriate immunization at
12 months (OR: 3.46; 95% CI: 1.51-7.92, p=0.003)
while as increased household size (≥ 2 children) was
negatively associated with on time administration of vac-
cines (OR: 0.41; 95% CI: 0.19-0.90, p=0.026) at 24 months.
Finally, children of mothers with higher academic educa-
tion presented lower odds of age-appropriate immunization
with all three newly introduced vaccines (OR: 0.42; 95%
CI: 0.19-0.94, p=0.035) at 24 months. Results from
univariate logistic regression models corresponding to
the associations in Tables 5 and 6 are presented in as
additional data [see Additional file 2: Tables S2 and S3] for
comparability reasons.
Discussion
The present study provides important information
regarding immunization coverage with traditional and new
vaccines, as well as predictive factors for complete and age-
appropriate vaccination of preschool children visiting public
nurseries of the municipal district of Athens. Our results
show that overall immunization rates and vaccination with
primary series of traditional vaccines were satisfactory,
except for hepatitis B, but the administration of booster
doses was delayed. However, overall vaccination coverage
was lower for newer vaccines, the most critical finding
being the significant delay in administering the primary
series of Men C and PCV7. The use of multivalent vaccines
was a positive contributor in timely administration of all
vaccines while a negative effect was noted with increasing
household size. Child’s increasing age was strongly associ-
ated with incomplete vaccination with all vaccines, while as
immigrant status was a predictor of incomplete and delayed
administration of all traditional vaccines, only. Finally,
higher maternal education was associated with delayed
administration of all newly licensed vaccines.
Regular assessment of vaccination coverage in a given
country is a significant tool to improve the effectiveness
of vaccination programs, but monitoring of vaccine uptake
at a local level is also required in order to prevent vaccine
preventable disease outbreaks due to susceptible subgroups
[7,26-28]. Moreover, apart from monitoring coverage,
it is necessary to identify characteristics or factors,
associated with under- vaccination in order to develop
appropriate strategies to increase compliance with
immunization schedules [10,11,29].
According to our findings, rates of complete overall
vaccination coverage of preschoolers against diphtheria,
tetanus, pertussis, poliomyelitis, Haemophilus influenzae
type b, as well as hepatitis B, were proven satisfactory,
exceeding 94%. As expected, overall uptake of Hib and
Table 4 Number and weighted proportions for age- appropriate and complete immunization of the study population
Age appropriate immunization at: Complete immunization
Vaccine 12 months 24 months 60 months (n=731)
(n=731) (n=704) (n=56)
N (%) N (%) N (% ) N (%)
DTP/DTaP 696 (95.4) 594 (84.8) 19 (33.7) 688 (94,2)
OPV /IPV 629 (86.8) 602 (86.2) 22 (38.8) 723 (98.9)
Hib 688 (94.2) 559 (80.0) 37 (65.6) 691 (94.5)
MMR - 660 (90.5) 20 (35.9) 462 (63.7)
HBV 202 (27.7) 605 (86.1) 55 (97.4) 688 (94.3)
MenC 164 (22.9) 111 (16.1) 7 (12.4) 671 (91.9)
PCV7 113 (16.0) 66 (9.8) 2 (4.0) 537 (73.1)
Var - 430 (60.4) 17 (30.1) 435 (61.1)
HAV - 6 (0.9) 41 (71.7) 450 (62.0)
All 5 traditional vaccines* (DTP/DTaP, OPV/ IPV, Hib, MMR, HBV) 163 (22.6) 417 (60.1) 4 (6.8) 414 (56.9)
All 3 new* (PCV7, Var, MenC) 62 (8.8) 35 (5.2) 1 (2.0) 327 (44.2)
DTP/DTaP: diphtheria, tetanus, pertussis/ acellular pertussis vaccine; OPV/IPV: live attenuated/inactivated polio vaccine; HBV: hepatitis B vaccine; MMR: measles,
mumps, rubella vaccine; Hib: haemophilus influenzae type b vaccine; Men C: conjugated meningococcal C vaccine; PCV7: conjugated pneumococcal 7-valent
vaccine; Var: varicella vaccine; HAV: hepatitis A vaccine.
* For age-appropriate vaccination at 12 months, the MMR vaccine is excluded from the traditional vaccines denominator and the HAV is excluded from the
new vaccines.
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possibly due to the widespread use and reimbursement of
multivalent vaccines, along with the continuous training
of primary care providers about the importance of early
protection against hepatitis B. Estimated vaccination
coverage with the newer vaccines Men C, PCV7, varicella,
and HAV was lower, varying between 61 and 92%, and this
may be explained by the recent introduction of these
vaccines in the Hellenic NIP and their even more recent
full reimbursement policy, only since 2008.
Age- appropriate immunization for older vaccines,
except for HBV, was satisfactory; however, this was only
true for primary series, with rates inversely associated as
age advanced, indicating a delay in administration of
booster doses. Efforts should be made to increase timely
vaccination with the first dose of MMR, which did not
exceed 90.5% at 24 months, and, even more so, to promote
earlier administration of the second dose, as only 63% of
our individuals had received their booster at the age of
5 years. The latter can be supported by the continuing
periodic measles outbreaks in our country due to under
immunized indigenous and immigrant population [7,30].
A remarkable result of this study, was the low rate of
complete vaccination coverage against hepatitis B before
the age of 12 months (27.7%), which has been a consistent
finding in other studies in our country [17,19,20]. A
possible explanation could be the lack of repayment
of the hexavalent vaccine by the nation’s largest social
security fund (ΙΚΑ), considering also that the majority
of our population was insured with this fund.In terms of the newest Men C, PCV7 and varicella
vaccines, timely vaccination was also found to diminish
with age. Nevertheless, the most striking finding was the
unacceptably small percentage of children immunized by
schedule against S. pneumoniae and N. meningitidis
serogroup C, before the age of 12 months. This lack of
compliance could be attributed to the high market price
of the above vaccines and the unfavorable refund policy
at the time of their introduction, pushing parents and
caregivers to delay vaccination in order to reduce the
number of required doses and therefore, cost. In
contrast, on time vaccination against varicella and
hepatitis A was higher, possibly as a result of the
simultaneous NIP introduction with reimbursement.
Although achieving a high overall childhood vaccination
coverage is important, on time administration of vaccine
doses deserves special attention as delays may pose a
significant risk for infectious diseases to young infants
and children [31,32]. It has been emphasized that delayed
administration of the first dose may jeopardize timely
administration of the following vaccines [33]. Proposed
solutions to address this problem include the creation
of reminder systems through the mail or telephone,
in addition to adequate training of, health workers
and parents, even during pregnancy and the neonatal
period [26,33,34]. In view of the recently introduced
nationwide electronic drug prescription policy by all
health professionals in our country, development of
immunization registries appears feasible. Moreover,
informing new parents in maternity hospitals about
Table 5 Multiple logistic regression derived odds ratios (and 95% Confidence Intervals) for the association between
sample characteristics and immunization with all 5 traditional vaccines (DTP/DTaP, OPV/IPV, MMR, Hib, HBV)
Complete immunization
(n=731)
Age appropriate immunization at
12 months (n=731) 24 months (n=704)
OR (95% CI) p OR (95% CI) p OR (95% CI) p
Actual age 0.37 (0.30-0.45) <0.001 0.83 (0.68-1.01) 0.058 0.85 (0.69-1.05) 0.850
Father’s nationality
Other Reference
Greek 1.56 (1.04-2.36) 0.034 0.98 (0.61-1.59) 0.930 2.57 (1.71-3.87) <0.001
Number of children
1 Reference
2 1.02 (0.69-1.50) 0.932 1.64 (1.03-2.62) 0.038 0.95 (0.63-1.42) 0.796
3+ 0.79 (0.48-1.32) 0.378 1.49 (0.83-2.69) 0.181 0.63 (0.37-1.06) 0.627
Maternal education
≤12 years Reference
>13 years 0.84 (0.59-1.18) 0.308 0.99 (0.68-1.46) 0.977 0.88 (0.61-1.27) 0.880
Use of multivalent vaccines
≤ 4-valent Reference
5- or 6-valent 1.30 (0.92-1.83) 0.138 3.00 (1.91-4.72) <0.001 3.19 (2.26-4.51) <0.001
Impact of vaccine cost on the decision to vaccinate
No Reference
Yes 0.88 (0.49-1.58) 0.657 0.85 (0.43-1.70) 0.651 0.51 (0.28-0.92) 0.025
Impact of insurance reimbursement on the decision to vaccinate
No Reference
Yes 0.94 (0.64-1.37) 0.741 1.06 (0.70-1.60) 0.800 0.99 (0.67-1.45) 0.949
Place of vaccination
Privately Reference
Insurance clinic / Public health clinic 1.17 (0.78-1.76) 0.440 0.97 (0.61-1.55) 0.907 0.88 (0.58-1.33) 0.543
Type of insurance
IKA Reference
Other 0.97 (0.63-1.48) 0.876 1.39 (0.87-2.22) 0.165 1.26 (0.82-1.94) 0.296
DTP/DTaP: diphtheria, tetanus, pertussis/ acellular pertussis vaccine; OPV/IPV: live attenuated/inactivated polio vaccine; HBV: hepatitis B vaccine; MMR: measles,
mumps, rubella vaccine; Hib: haemophilus influenzae type b vaccine.
IKA: Social Security Institute.
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contribute significantly to timely administration of the
first vaccine dose.
We found that the child’s age remained a strong pre-
dictor for incomplete immunization with older and newer
vaccines. Foreign ethnicity was significantly associated
both with incomplete and delayed administration of
all five traditional vaccines. Immigrant status as well
as belonging to other minority groups (Roma, various
religious groups) have been described as factors leading to
suboptimal vaccination worldwide and, therefore, the need
for targeted intervention in the aforementioned groups has
been underlined [21,35,36]. Interestingly, in the present
study, foreign born children presented lower vaccinationrates only for traditional vaccines, when compared to
native individuals, possibly indicating immunization
trends in their countries of origin. In contrast, vaccin-
ation coverage with newer vaccines did not differ, and
this could be indicative of improved compliance in a
controlled environment of their receiving country. In
light of the increasing inflow of refugee population from
countries of poor socioeconomic status in Greece, the need
for ongoing surveillance and targeted intervention is evident.
As described by other investigators [21,37,38], increasing
family size was associated with suboptimal, while as use of
multivalent formulations with increased compliance
for all vaccines, in our population. In addition, higher
maternal education was a negative contributor to
Table 6 Multiple logistic regression derived odds ratios (and 95% Confidence Intervals) for the association between
sample characteristics and immunization with all 3 newer vaccines (MenC, PCV7, Var)
Complete immunization
(n=731)
Age appropriate immunization at
12 months (n=731) 24 months (n=704)
OR (95% CI) p OR (95% CI) p OR (95% CI) p
Actual age 0.77 (0.65-0.91) 0.002 0.47 (0.35-0.64) <0.001 0.45 (0.29-0.71) 0.001
Father’s nationality
Other Reference
Greek 1.29 (0.88-1.90) 0.188 2.10(0.91-4.86) 0.082 2.95 (0.91-9.50) 0.071
Number of children
1 Reference
2 0.91 (0.64-1.31) 0.621 0.58 (0.31-1.09) 0.092 0.41 (0.19-0.90) 0.026
3+ 0.77 (0.48-1.22) 0.265 0.42 (0.18-1.01) 0.053 0.27 (0.08-0.89) 0.031
Maternal education
≤12 years Reference
>13 years 0.73 (0.53-1.02) 0.061 0.68 (0.38-1.22) 0.198 0.42 (0.19-0.94) 0.035
Use of multivalent vaccines
≤ 4-valent Reference
5- or 6-valent 1.09 (0.78-1.50) 0.630 3.46 (1.51-7.92) 0.003 2.24 (0.88-5.68) 0.090
Impact of insurance reimbursement on the decision to vaccinate
No Reference
Yes 0.95 (0.67-1.34) 0.764 1.22 (0.65-2.28) 0.538 1.28 (0.57-2.90) 0.551
Place of vaccination
Privately Reference
Insurance clinic / Public health clinic 1.39 (0.95-2.03) 0.086 0.64 (0.32-1.30) 0.216 0.56 (0.23-1.36) 0.199
Type of insurance
IKA Reference
Other 1.13 (0.77-1.66) 0.545 1.67 (0.84-3.34) 0.144 1.69 (0.70-4.11) 0.244
Men C: conjugated meningococcal C vaccine; PCV7: conjugated pneumococcal 7-valent vaccine; Var: varicella vaccine.
IKA: Social Security Institute.
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accordance with a number of reports describing that
parents of higher educational level may present lower
compliance to vaccine recommendations as a result of
their access to various information sources, increasing
their concern about vaccine safety [39-41].
Finally, we were not able to draw any firm conclusions
on the negative impact of cost on the decision of parents
to vaccinate their children. Nevertheless, the increasing
proportions of vaccination coverage among our study
population in comparison to previously described rates
[19] indicates that insurance reimbursement had a posi-
tive impact, a conclusion also validated by our model
findings, although not to a statistically significant degree.
The insignificant impact of cost on immunization in our
study may be partly explained by the small percentage of
guardians responding positively to the question of
whether cost would be a deciding factor for them (8.3%),
but also by the retrospective collection of information,comparing current parental beliefs towards vaccines that
had already been administered. However, the importance
of state’s funding policy has been clearly associated
with vaccination coverage in a number of studies, as
out-of- pocket costs have been inversely correlated
with optimal vaccine administration [42-45]. In view of
the economic crisis in our country, an increasing number
of children have no insurance for recommended vaccines
and visit, therefore, public health centers to receive im-
munization. In order to prevent immunization gaps, it is
essential to improve vaccine delivery in public facilities,
including schools, as well as maintaining full reimburse-
ment of all necessary vaccines.
Study limitations and strengths
The present study had a number of limitations. It was
conducted locally, among families of low and middle
income and is, therefore, not representative of the whole
country. Moreover, the municipal nurseries of Athens
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http://www.biomedcentral.com/1471-2458/13/908could be considered as a supervised environment since
the immunization records of all students are tested upon
registration and yearly thereafter. Although this could
overestimate vaccination coverage, it must be emphasized
that non- compliance to complete immunization gaps is
not a criterion to deny school entry. Nevertheless, the
above article provides significant evidence regarding
immunization, collected accurately through health
booklets, in the nation’s largest city hosting the majority
of native and immigrant population. Therefore, it could be
used as a model for designing strategies in order to
improve quality and effectiveness of vaccination programs
on a local basis.
Conclusions
Our results highlight the need to monitor uptake of
newly introduced vaccines and to develop an effective
vaccine reminder system, in order to encourage appropriate
administration of booster doses, as well as timely adminis-
tration of hepatitis B vaccine. Considering the recent intro-
duction of a nationwide electronic drug prescription policy,
the implementation of immunization registries in order to
improve the quality of vaccination programs, appears
feasible. Immigration, increasing number of siblings
and high maternal education were factors associated with
suboptimal immunization and may warrant targeted inter-
vention. The support of public health facilities, including
schools, as well as the maintenance of a full reimbursement
policy, are of paramount importance as gaps in insurance
benefits, in view of the economic crisis, could result in
missed vaccination opportunities in our country.
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